Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology

* Ipsen's Uro-Oncology pipeline strengthened, with a phase III product for the
    treatment of castrate-resistant prostate cancer
  * A potential companion drug for Ipsen's Decapeptyl(®)
  * A drug with a unique mechanism of action targeting angiogenesis and

Lund (Sweden) and Paris (France), April 18 2011 - Active Biotech AB (NASDAQ OMX
NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) announced today that they
have entered into a broad partnership to co-develop and commercialize Active
Biotech's investigational compound Tasquinimod "TASQ". A global Phase III trial
of TASQ in men with metastatic castrate-resistant prostate cancer (CRPC) was
recently initiated by Active Biotech and patient recruitment is ongoing.

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: "This new
partnership will broaden the scope of our uro-oncology franchise. Subject to the
success  of the ongoing phase III clinical trial for the treatment of metastatic
castrate-resistant  prostate  cancer  and  following  market approval, TASQ will
perfectly   fit  in  our  current  portfolio,  alongside  the  sustained-release
formulations  of Decapeptyl.  We continue to fulfill Ipsen's commitment to offer
physicians and patients a comprehensive range of complementary medical solutions
for the treatment of prostate cancer. We are excited to work with Active Biotech
as  this partnership leverages our longstanding and recognized expertise in this
severely debilitating disease."

"We are excited to initiate the development of TASQ with Ipsen, who has a proven
track  record and  strong R&D  capabilities within  prostate cancer. We consider
Ipsen  an ideal partner for Active Biotech  and with this partnership a powerful
development  and  commercialization  strategy  for  TASQ has been secured. "said
Tomas Leanderson, President & CEO of Active Biotech.

About the agreement
Under the terms of the agreement, Active Biotech granted Ipsen exclusive rights
to commercialize TASQ worldwide, except for North and South America and Japan
where Active Biotech retains all commercial and marketing rights. Both companies
will co-develop TASQ for the treatment of castrate-resistant prostate cancer,
with the possibility to develop TASQ in other cancer indications.

Active  Biotech is responsible for conducting  and funding the Phase III pivotal
clinical  trial and  will receive  up to  €200 million  consisting of an upfront
payment  of €25 million  and additional payments  contingent upon achievement of
clinical,  regulatory and  commercial milestones.   In addition,  Ipsen will pay
Active  Biotech progressive  double-digit royalties  on its  net sales  and will
conduct  and fund a European supportive study in prostate cancer patients out of
its  R&D  budget.  Eventual  costs  to  develop  TASQ  in  future  other  cancer
indications will be shared.

About TASQ
TASQ (tasquinimod, ABR-215050) binds to a molecule called S100A9 which is
expressed in the white blood cells involved in the regulation of immune
responses. S100A9 interacts with two known pro-inflammatory receptors (Toll like
receptor 4 (TLR4) and receptor of advanced glycation end products (RAGE)) and
this interaction is inhibited by TASQ (Björk et al PLoS Biology, April 2009).

The  development  of  TASQ  is  currently  focused  on the treatment of prostate
cancer.  TASQ is an antiangiogenic compound, meaning that it cuts off the supply
of  nutrients to  the tumor.  Up-regulation of  thrombospondin-1 (TSP1) has been
identified  as one  important component  in order  to understand and explain the
anti-angiogenic  mechanism of TASQ  treatment of prostate  cancer (Olsson et al,
Mol Cancer May 2010).

The   previously   concluded   clinical  trial  was  a  2:1 randomized,  placebo
controlled,  double-blind Phase  II trial  investigating up  to 1 mg/day of TASQ
versus  placebo in 206 asymptomatic patients  with metastatic castrate resistant
prostate  cancer (CRPC). The primary endpoint, patients with disease progression
at  six months, was  reached. The results  showed that the  fraction of patients
with  disease  progression  during  the  six-month  period  was 31% for patients
treated  with TASQ  compared with  66% for placebo-treated  patients. The median
progression-free  survival was 7.6 months  for the TASQ  group, compared to 3.3
months  for the placebo group  (p=0.0042). TASQ treatment also  had an effect on
biomarkers  relevant  for  prostate  cancer  progression  and was generally well

The  ongoing clinical trial (funded by  Active Biotech) is a global, randomized,
double-blind,  placebo-controlled Phase  III trial  in patients  with metastatic
CRPC.  The aim  of the  study is  to confirm  TASQ's effect on the disease, with
radiological progression-free survival (PFS) as the primary endpoint and overall
survival  as the secondary endpoint. The study will include about 1,200 patients
in more than 250 clinics (

About Prostate Cancer
Prostate cancer is the most common cancer form among men. Its occurrence is
strongly age-related and it is very rare before the age of 50. Prostate cancer
has highly varying degrees of severity. Despite a relatively good prognosis,
prostate cancer is the second most common cause of cancer death among men.

Every  year  about  220,000 new  cases  are  diagnosed in the US alone (American
Cancer  Society 2010) and 226 000 new cases for European G5 (Datamonitor 2010).
The  global  market  for  drugs  used  in  the  treatment of prostate cancer was
estimated at USD 5.4 billion for 2009 (GlobalData 2010).

About Ipsen's pipeline in uro-oncology
Ipsen's pipeline in uro-oncology contains Decapeptyl(®). The active substance in
Decapeptyl® is triptorelin, a decapeptide analogue of GnRH (Gonadotrophin
Releasing Hormone), a hormone secreted by the hypothalamus, which initially
stimulates the release of pituitary gonadotrophins (hormones produced by the
pituitary gland), which in turn control hormonal secretions by the testes and
ovaries. Decapeptyl(®) contains a formulation that was initially developed and
continues to be used mainly in the treatment of advanced metastatic prostate
cancer. Additional indications have been subsequently developed.
Decapeptyl(®) is available in monthly or quarterly sustained-release
formulations, as well as a daily formulation. In addition, Ipsen and its partner
Debiopharm submitted a marketing authorization application for 6-month
triptorelin 22.5 mg in Europe in September 2008. Ipsen and Debiopharm announced
the completion of the European decentralized registration procedure for the 6-
month sustained-release formulation of Decapeptyl(®). This formulation is
therefore available in some countries of the European market since 2010.

Decapeptyl(®)  was initially launched  in France in  1986. At 31 December 2010,
Decapeptyl(®) had marketing authorizations in over 60 countries, including 21 in

About Ipsen
Ipsen is a global biopharmaceutical group, with sales exceeding €1.1 billion in
2010. The Group has total worldwide staff of more than 4,400 employees, of which
more than 900 contribute to the discovery and development of innovative drugs
for patient care. Ipsen's development strategy is based on fast growing
specialty care drugs in oncology, endocrinology, neurology and hematology and on
primary care drugs. This strategy is supported by an active policy of
partnerships. Ipsen's research & development (R&D) centers and its peptide &
protein engineering platform give the Group a strong competitive edge. In 2010,
R&D expenditure totaled more than €220 million, above 20% of Group sales.
Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN
code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD").
The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level
I American Depositary Receipt (ADR) program, which trade on the over-the-counter
market in the United States under the symbol IPSEY. For more information on

About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy, primarily of
renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDexTM for RA. Please visitwww.activebiotech.comfor more information.

For further information:

Active Biotech
Tomas Leanderson                   Göran Forsberg

President & CEO                    VP Investor Relations & Business Development
Tel: +46 (0)46 19 20 95            Tel: +46 (0)46 19 11 54

Didier Véron

Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58

Financial Community
Pierre Kemula                  Stéphane Durant des Aulnois

Investor Relations Officer     Investor Relations Manager
Tel.: +33 (0)1 58 33 60 08     Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63      Fax: +33 (0)1 58 33 50 63

Ipsen's forward Looking Statement

The  forward-looking  statements,  objectives  and  targets contained herein are
based  on the Group's  management strategy, current  views and assumptions. Such
statements  involve known  and unknown  risks and  uncertainties that  may cause
actual   results,   performance  or  events  to  differ  materially  from  those
anticipated  herein.  Moreover,  the  targets  described  in  this document were
prepared  without taking into account  external growth assumptions and potential
future  acquisitions,  which  may  alter  these parameters. These objectives are
based on data and assumptions regarded as reasonable by the Group. These targets
depend  on  conditions  or  facts  likely  to  happen  in  the  future,  and not
exclusively  on  historical  data.  Notably,  future  currency  fluctuations may
negatively  impact the profitability of  the Group and its  ability to reach its
objectives. Actual results may depart significantly from these targets given the
occurrence  of certain  risks and  uncertainties. The  Group does not commit nor
gives  any guarantee that it will meet the targets mentioned above. Furthermore,
the  Research  and  Development  process  involves  several stages each of which
involve  the substantial risk that the Group  may fail to achieve its objectives
and  be forced to abandon its efforts with  regards to a product in which it has
invested significant sums. Therefore, the Group cannot be certain that favorable
results  obtained  during  pre-clinical  trials  will  be confirmed subsequently
during  clinical  trials,  or  that  the  results  of  clinical  trials  will be
sufficient  to  demonstrate  the  safe  and  effective  nature  of  the  product
concerned. The Group also depends on third parties to develop and market some of
its  products  which  could  potentially  generate  substantial royalties; these
partners  could behave  in such  ways which  could cause  damage to  the Group's
activities  and financial results. The  Group expressly disclaims any obligation
or  undertaking to update  or revise any  forward looking statements, targets or
estimates  contained  in  this  press  release  to reflect any change in events,
conditions, assumptions or circumstances on which any such statements are based,
unless  so required by  applicable law. The  Group's business is  subject to the
risk  factors  outlined  in  its  registration  documents  filed with the French
Autorité des Marchés Financiers.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:

This  press release  contains certain  forward-looking statements. Such forward-
looking  statements  involve  known  and  unknown risks, uncertainties and other
important   factors   that  could  cause  the  actual  results,  performance  or
achievements  of the company, or industry results, to differ materially from any
future  results,  performance  or  achievement  implied  by  the forward-looking
statements.  The company does not undertake any obligation to update or publicly
release   any   revisions  to  forward-looking  statements  to  reflect  events,
circumstances or changes in expectations after the date of this press release.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was provided to the media for publication on April 18, 2011, at 07.30 CET.

Active Biotech and Ipsen enter into a broad partnership:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE